Management of metastatic colorectal cancer: The impact of clinical trials reported at ASCO 2007

Community Oncology

Volumn 5, Issue 1, 2008, Pages 37-42

  Saltz, Leonard ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN E; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGISTRY; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL GROWTH; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CROSS REACTION; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE REACTION; MEDICAL SOCIETY; METASTASIS; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PROGNOSIS; PROTEIN SECRETION; RASH; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 38949110269     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70182-6     Document Type: Review

References (29)

1. American Cancer Society. Colorectal Cancer Facts & Figures. Atlanta, Ga: American Cancer Society, 2005. Available at: http://www.cancer.org/ downloads/STT/ CAFF2005CR4PWSecured.pdf. Accessed October 25, 2007.
2. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Based on November 2006 SEER data submission, posted to the SEER web site, 2007. Bethesda, MD: National Cancer Institute. Available at: http://seercancergov/csr/1975_ 2004/. Accessed July 27, 2007.
3. Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006;95:131-138.
4. National Cancer Institute. Colon Cancer (PDQ): Treatment. Available at: http://www. cancer.gov/cancertopics/pdq/treatment/colon/ HealthProfessional/ page9. Accessed July 27, 2007.
5. rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. Available at: http:// www.asco.org/portal/site/ASCO/menuitem. c608d82cf53347fd506fe310ee37a01d/?abstractID=224&confID=47&vmview= edbk_detail_ew&vgnextoid=c759201eb61a7010VgnVCM100000ed730ad1RCRD& CookiesSet=1:224228. Accessed July 27, 2007.
6. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
8. Saltz L, Clark S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/N016966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007;25(18S):4028.
9. Grothey A, Sugrue M, Hedrick E, et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). J Clin Oncol 2007;25(18S):4036.
10. Kozloff M, Hainsworth J, Badarinath A, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J Clin Oncol 2006;24(18S):3537.
11. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
12. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007;25(18S):4000.
13. Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park) 2006;20:1373-1382.
14. Chung CH, Chan E, Berlin J, et al. Cetuximab-related hypersensitivity reactions associated with pre-existing cetuximab-specific IgE antibody. J Clin Oncol 2007;25(18S):9097.
15. Fuchs C, Marshall J, Mitchell EP, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: updated efficacy data. J Clin Oncol 2007;25(18S):4027.
16. O'Connell MJ. Survival following recurrence in patients with adjuvant colon cancer: findings from the 20,800-patient ACCENT dataset. J Clin Oncol 2007;25(18S):4009.
17. rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL.
18. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
19. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 2007;25(18S):4007.
20. rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL.
21. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. J Clin Oncol 2007;25(18S):4013.
22. rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL.
23. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
24. Punt CJ, Koopman M, Douma J, et al. Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): a Dutch Colorectal Cancer Group (DCCG) phase III study. J Clin Oncol 2007;25(18S);4012.
25. rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL.
26. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007;25(18S):LBA5.
27. Amgen discontinues vectibix(TM) treatment in PACCE trial evaluating Vectibix(TM) as part of triple combination regimen [news release]. Thousand Oaks, CA: Amgen Inc; March 22, 2007. http://wwwext.amgen.com/ media/media_pr_detail.jsp?year=2007&release ID=977186. Accessed July 27, 2007.
28. Amgen's fourth quarter 2006 revenue increased 17% to $3.8 billion; full year 2006 revenue increased 15% to $14.3 billion [news release].Thousand Oaks, CA: Amgen Inc; January 25, 2007. http://www.amgen.com/ media/media_pr_detail.jsp?year=2007&releaseID=954402. Accessed October 25, 2007.
29. Hecht J, Chidiac T, Mitchell E, et al. An interim analysis of efficacy and safety from a randomised controlled trial of panitumumab with chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (MCRC). Presented at the 9th World Congress on Gastrointestinal Cancer; June 27-30, 2007; Barcelona, Spain.